Abbott Dumps Generic Drugs Business, Looks For More Device Targets
This article was originally published in The Gray Sheet
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.
You may also be interested in...
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.
Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.
An expert panel foresees increased adoption of digital tools in the OR, not just robotics. These tools help surgeons make more informed decisions and improve outcomes, but barriers remain.